Literature DB >> 25937448

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.

Nikolai V Ravin1, Elena A Blokhina2, Victor V Kuprianov2, Liudmila A Stepanova3, Aram A Shaldjan3, Anna A Kovaleva3, Liudmila M Tsybalova3, Konstantin G Skryabin2.   

Abstract

The extracellular domain of the transmembrane protein M2 (M2e) of influenza A virus is a promising target for the development of "universal" vaccines against influenza. M2e is a poor immunogen by itself; however, when M2e is linked to an appropriate carrier, such as hepatitis B virus core (HBc) particles, it becomes highly immunogenic. Insertions of target peptides into the surface-exposed major immunodominant loop region (MIR) of the HBc antigen are especially immunogenic, but such insertions often affect the protein folding and formation of recombinant virus-like particles. To facilitate an appropriate conformation of the M2e insert, we introduced flexible linkers at the junction points between the insert and flanking HBc sequences. This approach allowed the construction of recombinant HBc particles carrying 1, 2 and 4 copies of M2e in the MIR region. These particles were produced in Escherichia coli and purified to homogeneity. The immune response and protective activity of hybrid HBc particles in mice correlated with the number of inserted M2e peptides: the highest immunogenicity and complete protection of mice against the lethal challenge by influenza virus was observed with particles carrying four copies of M2e. The possibility of the simultaneous presentation of M2e peptides from several important influenza strains on a single HBc particle could also facilitate the development of a broad-specificity vaccine efficient not only against influenza A strains of human origin but also for newly emerging strains of animal origin, such as the avian influenza.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HBc particle; Influenza virus; M2e; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25937448     DOI: 10.1016/j.vaccine.2015.04.066

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.

Authors:  Yiwen Zhao; Zhuofan Li; Jewel Voyer; Yibo Li; Xinyuan Chen
Journal:  ACS Appl Mater Interfaces       Date:  2022-04-25       Impact factor: 10.383

2.  Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes of Toxoplasma gondii Against Acute and Chronic Toxoplasmosis in Mice.

Authors:  Jingjing Guo; Aihua Zhou; Xiahui Sun; Wenchao Sha; Kang Ai; Ge Pan; Chunxue Zhou; Huaiyu Zhou; Hua Cong; Shenyi He
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 3.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

4.  Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide.

Authors:  Anna A Zykova; Elena A Blokhina; Roman Y Kotlyarov; Liudmila A Stepanova; Liudmila M Tsybalova; Victor V Kuprianov; Nikolai V Ravin
Journal:  Viruses       Date:  2020-10-06       Impact factor: 5.048

5.  Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection Against Antigenically Divergent H7N9 Virus in Chickens.

Authors:  Dexin Kong; Taoran Chen; Xiaolong Hu; Shaorong Lin; Yinze Gao; Chunmei Ju; Ming Liao; Huiying Fan
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

6.  Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.

Authors:  Yan Guo; Lei He; Nianping Song; Pei Li; Shihui Sun; Guangyu Zhao; Wanbo Tai; Shibo Jiang; Lanying Du; Yusen Zhou
Journal:  Microbes Infect       Date:  2017-09-10       Impact factor: 2.700

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.